Objective-B-cell depletion therapy is widely used for treatment of cancers and autoimmune diseases. B cells are abundant in abdominal aortic aneurysms (AAA); however, it is unknown whether B-cell depletion therapy affects AAA growth. Using experimental models of murine AAA, we aim to examine the effect of B-cell depletion on AAA formation. Approach and Results-Wild-type or apolipoprotein E-knockout mice were treated with mouse monoclonal anti-CD20 or control antibodies and subjected to an elastase perfusion or angiotensin II infusion model to induce AAA, respectively. Anti-CD20 antibody treatment significantly depleted B1 and B2 cells, and strikingly suppressed AAA growth in both models. B-cell depletion resulted in lower circulating IgM levels, but did not affect the levels of IgG or cytokine/ chemokine levels. Although the total number of leukocyte remained unchanged in elastase-perfused aortas after anti-CD20 antibody treatment, the number of B-cell subtypes was significantly lower. Interestingly, plasmacytoid dendritic cells expressing the immunomodulatory enzyme indole 2,3-dioxygenase were detected in the aortas of B-cell-depleted mice. In accordance with an increase in indole 2,3-dioxygenase+ plasmacytoid dendritic cells, the number of regulatory T cells was higher, whereas the expression of proinflammatory genes was lower in aortas of B-cell-depleted mice. In a coculture model, the presence of B cells significantly lowered the number of indole 2,3-dioxygenase+ plasmacytoid dendritic cells without affecting total plasmacytoid dendritic cell number. Conclusions-The present results demonstrate that B-cell depletion protects mice from experimental AAA formation and promotes emergence of an immunosuppressive environment in aorta. are co-senior authors.
O ne of the most commonly clinically utilized B-cell depletion drugs is Rituximab, a chimeric murine/human monoclonal IgG targeting cells expressing CD20. It was first approved for the treatment of non-Hodgkin lymphoma and has demonstrated efficacy in the treatment of multiple CD20positive B-cell malignancies, including chronic lymphocytic leukemia. After its approval for the treatment of rheumatoid arthritis, clinical use rituximab has been increased. 1 Rituximab specifically depletes pre-and mature B cells but not the pro-B cells, plasma B cells or other cell immune types. 2 Afflicting primarily elderly men and smokers, abdominal aortic aneurysms (AAA) carry significant morbidity and mortality remaining the 15th leading cause of death in the United States. 3 Approximately 200 000 patients are diagnosed each year with AAA and nearly 15 000 are in danger of rupture.
Infiltration of immune cells has been strongly correlated with AAA formation and rupture. 4 Importantly, quantitative analysis of human AAA tissue demonstrated that 41% of infiltrating mononuclear cells are B cells. 5 We have previously reported infiltration of both B1 and B2 subtypes in murine experimental AAA. 6 The muMT mice, which are genetically deficient in B cells, develop AAA similar to the wild-type (WT) mice, whereas adoptive transfer of B2 cells to muMT mice suppressed aneurysm formation. 6 B cells have also been reported to promote mobilization of monocytes from spleen to the AAA in response to angiotensin II (Ang II) in apolipoprotein E-knockout (KO) mice. 7 However, it is still unknown whether B-cell depletion is protective or deleterious for experimental murine AAA.
On the basis of our results obtained from muMT mice, we hypothesized that B-cell-depleted mice were prone to AAA formation. To test the hypothesis, we used anti-CD20 antibody-mediated B-cell depletion strategy in both elastase perfusion and Ang II infusion models of mouse AAA. We used flow cytometry to quantify B-cell depletion and characterize immune cells in AAA, spleen, blood, thymus, and bone marrow; multiplex assay to quantify circulating cytokines/chemokines; and real-time reverse transcription polymerase chain reaction to quantify inflammatory gene expression in aorta.
Materials and Methods

Materials and Methods are available in the online-only Data Supplement
Results
Murine Anti-CD20 Antibody Significantly Depletes Both B1 and B2 Cells and Protects Mice From AAA Formation
To examine effectiveness of the B-cell depletion antibody, WT mice were injected intraperitoneally or intravenously with anti-CD20 or control antibodies, and after 7 days, B1 and B2 cells were examined from blood, spleen, and peritoneal fluid using flow cytometry ( Figure 1A ). B1 cells were identified as CD19hiB220lo and B2 cells as CD19loB220hi. 6, 8 B1 cells are known to be predominantly located in the peritoneal cavity in mice 9,10 and our results confirmed these findings ( Figure 1B ). Notably, both intraperitoneal and intravenous injection of anti-CD20 antibody resulted in a significant decrease in B1 cells. B2 cells were more prominent in spleen and blood and 85% to 95% of B2 cells were depleted at day 7 after both intraperitoneal and intravenous treatments ( Figure 1B ). However, intraperitoneal treatment depleted B2 cells in peritoneal fluid more efficiently compared with intravenous treatment. Altogether, these results demonstrate anti-CD20 treatment significantly depleted B cells in WT mice after 7 days of treatment.
To examine whether B-cell depletion affects AAA formation, an elastase perfusion model of AAA was first used. A single dose of anti-CD20 treatment maintains depletion of B cells for 3 to 8 weeks. 11, 12 However, to prevent reappearance of B-cell subtypes, we followed previously published anti-CD20-mediated B-cell depletion strategy in mice, 13 in which the WT mice were given 2 doses of anti-CD20 or control antibodies, the first on day 7 before elastase perfusion and the second on day 7 after elastase perfusion of abdominal aorta ( Figure 1A) . As a negative control, abdominal aortas were perfused with heat-inactivated elastase. At day 14 after elastase perfusion, mice were anesthetized, aortic diameters were measured, and the perfused aorta, blood, peritoneal fluid, bone marrow, thymus, and spleen were collected for the analysis of B-cell depletion. Compared with single dosing, 2 doses anti-CD20 treatment (intraperitoneal or intravenous) depleted >95% of both B1 and B2 cells in various tissues, including spleen and the elastase-perfused aortas ( Figure 2A ; Figure I in the online-only Data Supplement). This method also depleted B1a, B1b, and B2 cells in peritoneal fluid as determined by 2 methods of B-cell characterization ( Figure II in the online-only Data Supplement). Only a midCD19+B220+ population was preserved in bone marrow of anti-CD20-treated animals representing previously described pro-B or long-lived plasma cells that do not express CD20 2 ( Figure I in the onlineonly Data Supplement). Aortic perfusion with active elastase induced a significant increase in aortic diameter, that is, AAA formation compared with perfusion of heat-inactivated elastase ( Figure 2B ). AAA formation was similar in control antibodytreated intraperitoneal and intravenous groups. In contrast to our hypothesis, B-cell depletion strikingly suppressed AAA formation (intraperitoneal: control versus anti-CD20, 97.9±7.4 versus 62.2±4.7%, P<0.01; intravenous: control versus anti-CD20, 97±6.6 versus 55±3.8%, P<0.05; n=8-9; Figure 2B ). In accordance with protection from AAA, elastase-perfused aortas of both intraperitoneal and intravenous anti-CD20 antibody-treated groups displayed marked preservation of elastin layers and smaller adventitial area ( Figure 2C ). Altogether, these results suggest that anti-CD20 antibody treatment significantly depleted B cells in various tissues independent of delivery method of anti-CD20 antibody and protected mice from AAA formation.
To confirm this protective effect of B-cell depletion in another model, we utilized an Ang II infusion model of murine AAA 14 in a small group of male apolipoprotein E-KO mice (n=5-6). The mice were treated with anti-CD20 or control antibodies 7 days before the Ang II infusion (at 1000 ng/kg per minute) via subcutaneous osmotic pumps ( Figure IIIA in the online-only Data Supplement). Repeat doses of antibodies were given on days 7 and 21 after pump implantation. As a negative control, a group of apolipoprotein E-KO mice were infused with saline via osmotic pumps and were given control antibodies. The mice were euthanized on day 28 after Ang II infusion, and aortas were harvested. Stages of aneurysm were determined as described by Daugherty et al. 14 No aortic aneurysm pathology was observed in any saline-infused mice ( Figure III3B and III3C in the online-only Data Supplement). Ang II infusion in control antibody-treated mice resulted in mixed aortic aneurysm, such as no aneurysm (n=1), thoracic aortic aneurysm (n=1, stage I), AAA (stage II, n=1 and stage III, n=2), and ruptured thoracic aorta (n=1, stage intravenous). However, anti-CD20-treated mice were completely protected (n=5; Figure III3B and III3C in the online-only Data Supplement). Successful infusion of Ang II was confirmed via elevated level of plasma aldosterone ( Figure III3D in the online-only Data Supplement). Moreover, the anti-CD20-treated mice demonstrated marked preservation of elastin layers and smaller adventitial area in suprarenal aortas compared with Ang II-infused control antibody-treated mice ( Figure III3E in the online-only Data Supplement). Collectively, our results demonstrate that B-cell depletion protects mice from AAA formation via using 2 unique models of experimental murine AAA. immune cells. Importantly, IgM antibodies have been reported to be anti-inflammatory and protective in the settings of atherosclerosis, 9 whereas, B cell secreted interleukin-2 (IL-2), IL-4, tumor necrosis factor-α, IL-6, interferon-γ (IFN-γ), and IL-12 and tumor necrosis factor-α regulates type 1 and type 2 immune responses. 15 We speculated that B-cell depletion would preserve the IgM level or increase the level of anti-inflammatory cytokines. However, in our study, IgM levels were significantly lower (P<0.01), whereas, as described before by DiLillo et al, 16 IgG levels were similar in the B-cell-depleted mice compared with the control mice (Figures 3A) . Moreover, no significant differences were found in the plasma levels of pro-or anti-inflammatory factors, such as IL-1β, IL-6, tumor necrosis factor-α, RANTES (regulated on activation, normal T-cell-expressed and secreted), MIP (macrophage inflammatory protein)-1α, MIP-1β, IP-10, IL-13, Eotaxin, KC (keratinocyte chemoattractant), MIP-2, and MIG (monokine induced by gamma interferon), whereas, the levels of IL-2, IL-4, IL-5, IL-10, IL-17, IL-12-p70, and IFN-γ were below the detection in the control and B-cell-depleted mice (Figures 3B) . Altogether, these results suggest that changes in circulating levels of immunoglobulins, cytokines, or chemokines are not the mechanism for attenuation of AAA in the B-cell-depleted mice.
Circulating Factors in the B-Cell-Depleted Mice
Anti-CD20 Antibody Treatment Does Not Abrogate Aortic Infiltration of Leukocytes
Aortic infiltration of immune cells has been strongly associated with AAA formation 17 ; therefore, we examined the Figure 4A ). Quantification of immunostaining revealed significantly less macrophage content and a trend toward lower neutrophil content in the aortas of B-cell-depleted mice compared with the control antibody-treated mice ( Figure 4B ). Next, we utilized flow cytometry to define and quantify the immune cells in AAA tissues. For cell counting, specifically the elastase-perfused portion of abdominal aorta was harvested ( Figure IVA in the online-only Data Supplement), perfused with heparin-PBS solution ex vivo. Each isolated aorta was digested separately with an enzymatic cocktail, stained with fluorescent-conjugated antibodies, and counting beads were added before running on a flow cytometer. As a control, the number of immune cells in spleen was counted. The gating strategy used for phenotyping immune cells is shown in Figure IVB in the onlineonly Data Supplement. The results revealed that the number of mononuclear leukocytes (CD45+ cells) was significantly lower in the spleen of anti-CD20-treated mice; however, no The plots have been gated for singlets, live CD45+ cells. B, Increase in aorta diameter in WT mice treated with 2 doses of control or anti-CD20 antibody via IP or IV. ∆ Elastase and Elastase indicate aortic perfusion with heat-inactivated elastase and elastase, respectively (n=8-9). After 1-way ANOVA, parametric unpaired t test was applied to determine significant differences between the groups. C, Representative images showing AAA sections stained for Verhoeff-Van Gieson (VVG; elastic fibers, black). A small segment of images acquired in 4× is shown in ×20 magnification. Scale bar in 4× images is 500 µm and in 20× images is 50 µm. Elastic fiber area (presented as percentage of total aortic area) and adventitial area were determined using ImageJ. After 1-way ANOVA, nonparametric t test (Mann-Whitney test) was applied to determine significant differences between the groups. Values are expressed as means±SEM and *, **, and *** indicate P<0.05, 0.01, and 0.001, respectively. significant difference was observed in the aortas ( Figure 4C ). Furthermore, the spleen and aorta from control antibodytreated mice demonstrated the presence of B1 and B2 cells, as well as IgM+IgD+ B1 and B2 cells, the numbers of which were significantly lower or absent in anti-CD20-treated mice ( Figure 4D ; Figure V in the online-only Data Supplement).
These results together suggest that immune cells accumulating in aorta may be creating an immunosuppressive microenvironment protecting the B-cell-depleted mice from AAA.
B-Cell Depletion Increases Aortic Infiltration of Immunosuppressive Cells
As the number of infiltrated leukocytes in the aorta was not affected after B-cell depletion, and B-cell-depleted mice were protected from AAA formation, we speculated that the absence of B cells created an immunosuppressive environment in aorta.
To investigate the presence of immunosuppressive cells, we first stained aortic cross sections from control and anti-CD20 antibody-treated mice for the presence of T and B cells using anti-CD3ε and anti-B220 antibodies, respectively ( Figure 5A ). CD3ε+ and B220+ cells stained in proximity to each other in AAAs from control antibody-treated mice, which was in accordance with our previously published literature. 6 CD3ε+ and, unexpectedly, B220+ cells were found in the AAAs of B-cell-depleted mice ( Figure 5A ). To confirm whether these B220+ cells were B cells, the aortic cross sections were stained with anti-B220 and anti-CD20 antibodies. Interestingly, 2 types of B220+ cells, that is, B220+CD20+ and B220+CD20− were identified in AAA of control antibody-treated mice, whereas, only B220+CD20− cells, although lesser in number, were present in the aorta of anti-CD20 antibody-treated mice ( Figure 5B ). To further characterize and quantify these B220+CD20− cells, we performed flow cytometry. The number of B220+ cells was significantly lower in the aortas of anti-CD20−treated mice compared with control antibody-treated mice (not shown). Furthermore, these B220+ cells in B-cell−depleted mice were identified as plasmacytoid dendritic cells (pDCs) expressing both CD317/plasmacytoid dendritic cell antigen-1 and B220. The pDCs were populated as hiCD317+B220+ and midCD317+B220+ in aorta ( Figure 5C ) and also in blood ( Figure VIA in the onlineonly Data Supplement) and spleen (not shown). In blood, the midCD317+B220+ population was a well-defined; however, in aorta, a large portion of the cell population (40.2±1.6% of mononuclear live CD45+CD4− cells, n=7) was CD317+ irrespective of control or anti-CD20 antibody treatment. A small population of pDC is known to express surface CD19 and intracellular immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) and plays a strong immunosuppressive role. [18] [19] [20] Therefore, we included CD19 and IDO antibodies in our flow cytometry antibody panel. Specifically, in the entire population of CD45+CD317+B220+ cells, only the midpopulation was CD19+ and strongly expressed IDO. CD19+IDO+ cells were undetected in hiCD317+B220+ and the number of midCD19+IDO+ cells was significantly higher in AAA ( Figure 5D ) and blood ( Figure  VIB in the online-only Data Supplement) of anti-CD20 antibodytreated mice. These results suggest that B-cell depletion increased aortic content of IDO-expressing pDCs. As the number of circulating IDO+ pDC was increased, we hypothesized that tryptophan catabolism would be increased systemically, leading to global immunosuppression after B-cell depletion. However, we did not find significant differences in the level of tryptophan and its metabolite kynurenine, or in the kynurenin:tryptophan ratio in circulation ( Figure VIC in the online-only Data Supplement), suggesting a recessive role of IDO-expressing pDCs in circulation.
IDO-expressing pDCs maintain the immunosuppressive environment by promoting regulatory T cell (Treg) generation in tissues. 21 Therefore, we quantified Tregs in aorta and spleen using flow cytometry. As reported before, 22 absolute Treg number, but not the proportion of Treg (expressed as percentage of CD4+ T cells), was significantly lower in spleen following anti-CD20-mediated B-cell depletion ( Figure 6A ). Staining of aortic cross sections with CD3ε and forkhead box P3 antibodies demonstrated presence of Tregs in aortas of control antibody and anti-CD20 antibody-treated mice ( Figure 6B ). Furthermore, flow cytometry revealed significantly higher Treg number and percentage (% of CD4+ T cells) in the aortas of anti-CD20-treated mice ( Figure 6C ). Altogether, these results suggest that B-cell depletion created an immunosuppressive microenvironment in aorta.
Next, to confirm the presence of an immunosuppressive environment, we examined local inflammatory gene expression in aortas using real-time reverse transcription polymerase chain reaction. The results demonstrated significant decrease in the expression of IFN-γ, IL-1β, and a trend in the reductions IL-6 and IL-10 in anti-CD20-treated mice; however, TGF-β expression was similar to the control antibody-treated mice ( Figure 6D ) confirming emergence of an immunosuppressive environment in aorta after B-cell depletion.
Presence of B Cells Lowers the Number of IDO+ pDCs
Chen et al 21 and Baban et al 23 have reported that the immunosuppressive IDO+ pDCs differentiate naive CD4 T cells to Tregs. However, it is unknown whether the presence of B cells affect the number of IDO+ pDCs. As the number of IDO+ pDC is increased in the B-cell-depleted mice, we hypothesized that B cells suppress IDO+ pDCs. To test this, we developed a coculture model. We used synthetic oligonucleotides containing unmethylated CpG oligodeoxynucleotide motifs to induce IDO expression in pDCs. 21, 23 First, the pDC-enriched cell fraction was collected from the spleen of WT mice using MACS column, and IDO expression was induced via treatment with class B CpG oligodeoxynucleotide 1826 in a 96-well culture plate for 48 hours (detail experimental method is described in the online Supplemental Material). As a control, pDCs were treated with control oligodeoxynucleotide 1826. The expression of pDC markers CD317 and B220 was found to be significantly increased in oligodeoxynucleotide 1826-treated pDCs ( Figure 7A through 7C). Again, only the midCD317+B220+ population was dominated with a high number of immunosuppressive CD19+IDO+ cells. Next, the entire B-cell population was isolated (via MACS column) from WT spleen, and various concentrations of B cells were cultured with IDO+ PDCs for 24 hours. Addition of increasing concentrations of B cells did not affect the number of pDCs; however, it significantly decreased the number of IDO+ pDC ( Figure 7D) . These results suggest that the presence of B cells suppresses the emergence of immunosuppressive IDO+ pDCs.
Discussion
Herein, we demonstrate that anti-CD20 treatment, whether injected by intraperitoneal or intravenous, strongly suppressed AAA formation in WT mice. The rationale for selecting 2 methods of delivery is that B1 cells are predominant in the peritoneal cavity, whereas B2 cells are in the spleen and blood of mouse. Patients, however, receive anti-CD20 treatment intravenously. We hypothesized that intravenous treatment would deplete more B2 cells in the spleen sparing the B1 cells in the peritoneal cavity, whereas intraperitoneal treatment would deplete more B1 cells in the peritoneal cavity sparing B2 cells in the spleen. After 7 days of anti-CD20 treatment, a significant depletion of circulating and splenic B1 and B2 cells was achieved; however, peritoneal B1 and B2 cells were resistant to depletion. Hamaguchi et al 24 reported a similar finding using a different clone of monoclonal anti-CD20 antibody. Interestingly, after 2 doses of anti-CD20 treatment, B1 and B2 cells were almost depleted in peritoneal cavity, spleen, blood, and bone marrow. In the same line, IgM level was significantly lower in the B-cell-depleted mice, which is primarily produced by B1 cells. We did not find a decrease in IgG levels, potentially because long-lived plasma B cells, which do not express CD20, are preserved in bone marrow after B-cell depletion and maintain circulating IgG levels. 16 In fact, our results demonstrated the presence of a midCD19+B220+ population in bone marrow after 2 doses of anti-CD20 antibody treatment. Although, further flow cytometry experiments are required for confirmation, the midCD19+B220+ population are most likely long-lived plasma cells.
pDCs are known to recognize viral-and bacterial-derived products and induce synthesis of type I interferon genes, such as IFN-α and IFN-β, and promote activation of a proinflammatory response via activating effector T cell, cytotoxic T cells, and natural killer cells. 25 On the contrary, tolerogenic pDCs express IDO and have potent immunomodulatory properties including the induction of Treg differentiation from naive CD4+ T cells. 23, 26, 27 Such tolerogenic pDCs seem to be representing a subset of pDCs and are tissue specific. 28, 29 Increased expression of IDO degrades tryptophan promoting immune tolerance or suppressing immune activation of neighboring cells. 30 Daissormont et al 31 have reported that pDCs are scarcely present in atherosclerosis and blocking IDO activity in pDCs exacerbates atherosclerosis. Our results provide the first evidence of emergence of IDO producing pDCs after the depletion of B cell in aorta using anti-CD20 antibody. In the context of aortic aneurysms, Tregs have been shown to suppress experimental murine AAA. 32 Importantly, patients with AAAs do not have functional circulating Tregs. 33 In our study, depletion of B cells increased the number of Tregs and IDOexpressing pDCs in aorta. In aortas of B-cell-depleted mice, Figure 5 Continued. a confocal microscope showing colocalized B220 (green) and CD20 (red) staining indicating B cells, and only B220 staining indicating dendritic cells (indicated by arrows) in AAA of control or anti-CD20 antibody-treated WT mice. * indicates lumen and --indicates luminal and exterior margins of aorta. C, Representative flow cytometry plots showing gating and increase in concentration of midB220+CD317+CD19+IDO in AAA after control or anti-CD20 antibody via intravenous (IV). The cells have been gated for singlets, live, CD45+, and CD4− mononuclear cells. D, Quantification of total pDCs and IDO+ pDCs in aorta (n=3-5). Nonparametric t test (Mann-Whitney test) was applied to determine significant differences between the groups. Values are expressed as means±SEM; * indicates P<0.05. P values >0.05 are indicated on the top of the bars.
the IDO-expressing pDCs may create an immunosuppressive environment leading to a decrease in pro-inflammatory gene expression. It is unknown whether IDO-expressing pDCs would differentiate naive CD4 T cells to Treg or recruit Treg to the aorta after elastase perfusion. We found a significant increase in circulating IDO+ pDCs after B-cell depletion; however, this was not correlated with an increase in tryptophan degradation or increase in kynurenine synthesis. Although other tryptophan metabolites, such as anthranilic acid, were not measured, it is likely that the concentration of tryptophan metabolites is higher in AAA tissues compared with the circulating level underscoring tissue-specific role of tolerogenic pDCs. Moreover, possible role of IL-10-producing dendritic cell or T cell in the protection cannot be ruled out. However, our IDO+ pDC:B-cell coculture demonstrated that the presence of B cells significantly lowered the number of CD19+IDO+ pDCs. Our data are in consistent with a model that B cells control immunosuppressive effects of pDC by limiting IDO+ pDC population and regulate inflammation and AAA as shown in the graphic abstract. In support of this model, recently, Yun et al 34 demonstrate that aortic pDCs-expressing IDO protects against atherosclerosis via generation of Tregs.
We have previously reported that the muMT mice, genetically deficient in B cells, develop AAA similar to the WT mice, and adoptive transfer of B2 cells suppresses AAA formation in muMT mice, suggesting AAA formation is dependent on B-cell subsets. In this study, we created B-cell deficiency in mature WT mice by using anti-CD20 antibody, which affected the homeostasis of T cells, primarily by reducing T-cell number including Tregs in spleen as demonstrated by us and also reported previously by Lykken et al. 22 Interestingly, IDOexpressing pDC number was significantly increased in various tissues of B-cell-depleted mice. Moreover, B-cell depletion has also been shown to improve endothelial function and reduce systemic inflammation in patients with rheumatoid arthritis. 35 Therefore, further studies are needed to understand the paradox immune response in muMT and anti-CD20 antibody-mediated B-cell-depleted mice.
In our study, the B cells were depleted before the induction of AAA. It is unknown whether B-cell depletion would Figure 7 . Presence of B cells affects the number of indole 2,3-dioxygenase (IDO)+plasmacytoid dendritic cells (pDCs). A, Schematic representation of study design of IDO-expressing pDC:B-cell coculture. pDCs isolated from spleen of wild-type mice were treated with 0.2 µmol/L of oligodeoxynucleotide (ODN) 1826 or control ODN (Co-ODN 1826) for 2 d. Subsequently, the culture medium was removed and medium containing indicated concentrations of isolated splenic B cells were added. The coculture was continued for 24 h and expression of B220, CD317, CD19, and IDO was determined via flow cytometry. B, Representative flow plots showing midCD317+B220+ cells, which are further gated from the CD19+IDO+ population. C, Quantification of midCD317+B220+ cells (significant difference between co-ODN and each of the ODN-treated group is shown) and (D) quantification of CD19+IDO+ pDCs. Parametric unpaired t test was applied to determine significant differences between the groups. Values are expressed as means±SD and *, **, and *** indicate P<0.05, 0.01, and 0.001, respectively. suppress established experimental AAA in mice. It is also unknown whether AAA formation will still be suppressed after a long-term depletion of B cells. In support of our finding, Mellak et al 7 have reported that Ang II mobilizes monocytes from spleen to aorta in a B cell-dependent manner and promote AAA formation in the apolipoprotein E-KO mice. As far as atherosclerosis is concerned, there are reports supporting 34, 36 and contradicting 37 the protective role of IDOexpressing pDCs. Therefore, generation of pDC-specific IDO-KO mouse is required to confirm that IDO-expressing pDCs protect B-cell-depleted mice from AAA.
In conclusion, using 2 experimental models of murine AAA, we demonstrated that anti-CD20 antibody-mediated B-cell depletion increased the number of IDO-expressing pDCs and created an immunosuppressive environment that attenuated inflammatory gene expression and suppressed AAA growth. Although further mechanistic studies are needed, these findings have the potential to lead to the development of nonsurgical strategies to prevent aneurysm formation. Furthermore, this evidence suggests that patients undergoing B-cell depletion therapy may be protective from AAA formation.
